|
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
|
09/11/25
|
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
|
pdf
|
|
Bausch Health’s Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage® Non-Surgical System
|
09/05/25
|
Bausch Health’s Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage® Non-Surgical System
|
pdf
|
|
Bausch Health Launches YUN Probiotherapy™ ACN Skincare Line in Poland
|
09/01/25
|
Bausch Health Launches YUN Probiotherapy™ ACN Skincare Line in Poland
|
pdf
|
|
Bausch Health Launches YUN Probiotherapy™ ACN Skincare Line in Poland (Polish)
|
09/01/25
|
Bausch Health Launches YUN Probiotherapy™ ACN Skincare Line in Poland (Polish)
|
pdf
|
|
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
|
08/26/25
|
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
|
pdf
|
|
Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Quebec and Saskatchewan
|
08/21/25
|
Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Quebec and Saskatchewan
|
pdf
|
|
Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOMC (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Quebec and Saskatchewan (French)
|
08/21/25
|
Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOMC (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Quebec and Saskatchewan (French)
|
pdf
|
|
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
|
08/15/25
|
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
|
pdf
|
|
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
|
08/07/25
|
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
|
pdf
|
|
Bausch Health Announces Second Quarter 2025 Results
|
07/30/25
|
Bausch Health Announces Second Quarter 2025 Results
|
pdf
|
|
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
|
07/29/25
|
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
|
pdf
|
|
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
|
07/28/25
|
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
|
pdf
|
|
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
|
07/24/25
|
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
|
pdf
|
|
Bausch Health Appoints New Chief Accounting Officer
|
07/10/25
|
Bausch Health Appoints New Chief Accounting Officer
|
pdf
|
|
Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Ontario, Nova Scotia and two federal programs
|
07/09/25
|
Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Ontario, Nova Scotia and two federal programs
|
pdf
|
|
Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOMC (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Ontario, Nova Scotia and two federal programs (French)
|
07/09/25
|
Bausch Health, Canada Inc. treatment for acne vulgaris, PrCABTREOMC (clindamycin phosphate, adapalene and benzoyl peroxide gel), now available through public drug plans of Ontario, Nova Scotia and two federal programs (French)
|
pdf
|
|
Bausch Health’s Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh “I Wish I Knew” Campaign to Educate People About Xifaxan® (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
|
07/07/25
|
Bausch Health’s Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh “I Wish I Knew” Campaign to Educate People About Xifaxan® (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
|
pdf
|
|
Bausch Health to Announce Second Quarter 2025 Results on July 30
|
07/02/25
|
Bausch Health to Announce Second Quarter 2025 Results on July 30
|
pdf
|
|
Bausch Health Partners with YUN to Bring Pioneering Microbiome Skincare to Poland (English)
|
06/23/25
|
Bausch Health Partners with YUN to Bring Pioneering Microbiome Skincare to Poland (English)
|
pdf
|
|
Bausch Health nawiązuje współpracę z YUN, aby wprowadzić przełomową pielęgnację mikrobiomu skóry do Polski (Polish)
|
06/23/25
|
Bausch Health nawiązuje współpracę z YUN, aby wprowadzić przełomową pielęgnację mikrobiomu skóry do Polski (Polish)
|
pdf
|
|
Bausch Health Announces 2025 Annual Meeting of Shareholder Results
|
05/14/25
|
Bausch Health Announces 2025 Annual Meeting of Shareholder Results
|
pdf
|
|
Xifaxan® (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
|
05/06/25
|
Xifaxan® (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
|
pdf
|
|
Bausch Health Announces First Quarter 2025 Results
|
04/30/25
|
Bausch Health Announces First Quarter 2025 Results
|
pdf
|
|
Bausch Health Announces Health Canada Clearance of Solta Medical’s Thermage® FLX System (English)
|
04/29/25
|
Bausch Health Announces Health Canada Clearance of Solta Medical’s Thermage® FLX System (English)
|
pdf
|
|
Bausch Health Announces Health Canada Clearance of Solta Medical’s Thermage® FLX System (French)
|
04/29/25
|
Bausch Health Announces Health Canada Clearance of Solta Medical’s Thermage® FLX System (French)
|
pdf
|
|
Bausch Health Announces Launch of Solta Medical’s Fraxel FTX™
|
04/25/25
|
Bausch Health Announces Launch of Solta Medical’s Fraxel FTX™
|
pdf
|
|
Bausch Health Announces Filing of Supplement to Proxy Statement
|
04/22/25
|
Bausch Health Announces Filing of Supplement to Proxy Statement
|
pdf
|
|
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich
|
04/17/25
|
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich
|
pdf
|
|
Bausch Health Announces Adoption of Shareholder Rights Plan
|
04/14/25
|
Bausch Health Announces Adoption of Shareholder Rights Plan
|
pdf
|
|
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program
|
04/10/25
|
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program
|
pdf
|
|
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
|
04/02/25
|
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
|
pdf
|
|
Bausch Health to Announce First Quarter Results on April 30
|
03/27/25
|
Bausch Health to Announce First Quarter Results on April 30
|
pdf
|
|
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
|
03/25/25
|
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
|
pdf
|
|
Bausch Health Announces Conditional Redemption of Senior Notes
|
03/21/25
|
Bausch Health Announces Conditional Redemption of Senior Notes
|
pdf
|
|
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
|
03/19/25
|
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
|
pdf
|
|
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
|
03/19/25
|
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
|
pdf
|
|
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
|
03/14/25
|
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
|
pdf
|
|
Bausch Health Announces Fourth Quarter and Full Year 2024 Results
|
02/19/25
|
Bausch Health Announces Fourth Quarter and Full Year 2024 Results
|
pdf
|
|
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
|
02/14/25
|
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
|
pdf
|
|
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
|
02/10/25
|
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
|
pdf
|
|
Bausch Health Provides Update on Strategic Alternatives
|
02/06/25
|
Bausch Health Provides Update on Strategic Alternatives
|
pdf
|
|
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
|
01/23/25
|
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
|
pdf
|
|
Bausch Health Statement on Selection of XIFAXAN® (rifaximin) for Inflation Reduction Act’s Medicare Negotiation Program
|
01/17/25
|
Bausch Health Statement on Selection of XIFAXAN® (rifaximin) for Inflation Reduction Act’s Medicare Negotiation Program
|
pdf
|
